Developer docs
API playgroundTry for free, no card

Search company profiles

Medicines Australia

Full company profile

uuid000ktf3

Namestring
Medicines Australia
Legal namestring
Medicines Australia
Company typeenum
Private
Founded yearint
1960
Descriptiontext

Medicines Australia is the peak industry body representing Australia's research-based pharmaceutical industry, with a history dating to 1960 when it first established its Code of Conduct. The organisation is a private, not-for-profit association headquartered in Deakin, ACT, with 11-50 employees, and is led by CEO Liz de Somer and Chair Sue MacLeman. Its members comprise companies that discover, develop, and manufacture prescription pharmaceutical products, biotherapeutic products, and vaccines in Australia — a roster that includes multinational majors such as Lilly, MSD, GSK, UCB, Amgen, Pfizer, Astellas, and Bristol Myers Squibb.

The association does not develop proprietary technology products. Its core offerings are policy advocacy, a self-regulatory Code of Conduct (currently Edition 19, with an interactive Edition 20 platform), the Strategic Agreement 2022-2027 with the Commonwealth Government, transparency reporting on industry payments to healthcare professionals, and educational programs including a Continuing Education Program. It also operates policy working groups covering the Access to Medicines Working Group, Clinical Trials / Research & Development Taskforce, Health Technology Assessment reform, the Oncology Industry Taskforce, the Pharma Australia Inclusion Group, and the Regenerative Medicines Consortium Programme.

Medicines Australia is funded entirely through recurring membership fees paid by its pharmaceutical company members; it does not sell commercial products or services. Its distribution is direct — engaging members through a Board of Directors, Advisory Council, policy working groups, briefings, and a member portal at members.medaus.com.au. The organisation's strategic significance to members derives from its role as the sole collective-bargaining counterparty to government on PBS access, HTA reform, clinical trials harmonisation, and intellectual property protection.

Short descriptiontext

Medicines Australia is the peak industry association representing research-based pharmaceutical companies in Australia, advocating on PBS access, HTA reform, and clinical trials policy since 1960, funded by member dues.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDeakin, Australia
HQ citystring
Deakin
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical industry advocacy, industry association services, health policy advocacy, code of conduct compliance, regulatory affairs representation
Industry3 codes
PRIMARYHLAIAKAL
Access Policy, Advocacy & Stakeholder Management
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYHLAJACAF
Health Technology Assessment (HTA) & Reimbursement Policy Bodies
Healthcare & Life Sciences/Public Health, Government & Regulators/Health Policy, Regulation & Compliance Authorities
SECONDARYBPADANAJ
Health, Pharmaceuticals & Medical Devices Regulatory Cooperation
Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation
SIC code1 code
  • Services-Health Services8000
Product category
Pharmaceutical Industry Association
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Membership fees
TypeSubscription Recurring
Description

Medicines Australia is funded through membership fees from pharmaceutical companies that discover, develop, and manufacture prescription pharmaceutical products, biotherapeutic products and vaccines in Australia.

medicinesaustralia.com.au
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Medicines Australia is the peak industry association representing research-based pharmaceutical companies in Australia. Its core activities include policy advocacy with the Commonwealth Government, negotiation and administration of the Strategic Agreement 2022-2027, administration of the Code of Conduct governing industry communication about prescription medicines, member services and working groups (AMWG, RDTF, Oncology Industry Taskforce, PAIG), and engagement on HTA reform, PBS access, and clinical trials harmonisation.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Medicines Australia is a peak industry body representing research-based pharmaceutical companies in Australia, not a product or technology company. Its offerings consist of industry advocacy, policy development, a Code of Conduct framework for member companies, publications (Annual Reports, Issues Briefs, Facts Book), educational programs (Continuing Education Program, Code workshops), transparency reporting systems, and advocacy resources. The organization does not offer commercial software products, SaaS platforms, or technology services.

Product and service5 records
1Strategic Agreement 2022-2027
CategoryPolicy and government engagement
Description

A 5-year framework agreement between Medicines Australia and the Australian Federal Government centred on earlier patient involvement, HTA reform, investment and savings measures, and policies for faster availability of new medicines in Australia. Applicable to member pharmaceutical companies.

2Medicines Australia Code of Conduct (Edition 19/20)
CategoryRegulatory and ethics framework
Description

Self-regulatory Code of Conduct governing the ethical promotion of prescription medicines and interactions with healthcare professionals. A TGA-imposed condition of registration for therapeutic goods that all member companies must comply with. Edition 20 is delivered via an interactive digital platform.

3Continuing Education Program (CEP)
4PharmAus 2025 Conference
CategoryEvents and conferences
Description

Annual flagship conference bringing together the pharmaceutical industry, government, and stakeholders for policy discussion, networking, and industry engagement.

5Working Together Guide
CategoryCommunity and stakeholder engagement
Description

A guide governing the relationships between Medicines Australia member companies and health consumer organisations, including financial and non-financial support arrangements and associated transparency reporting.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
1Commonwealth Government of Australia
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Medicines Australia has a 5-year Strategic Agreement (2022-2027) with the Federal Government focused on earlier patient involvement, HTA reform, and improving availability of new medicines in Australia. This includes investment and savings measures, and a reform agenda with policy improvements for faster access to medicines.

medicinesaustralia.com.au
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Internal policy working group focused on access to medicines issues, operating under the Strategic Agreement with government.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Federal, State and Territory Governments and clinical trial stakeholders to implement the National One Stop Shop and National Clinical Trials Front Door for harmonising clinical trial approvals across Australia.

4Oncology Industry Taskforce
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Industry taskforce focused on oncology medicines access and policy issues, representing member companies with oncology portfolios.

medicinesaustralia.com.au
5Pharma Australia Inclusion Group (PAIG)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Inclusion group focused on diversity and inclusion within the pharmaceutical industry in Australia.

medicinesaustralia.com.au
6Regenerative Medicines Consortium Programme
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Consortium programme focused on regenerative medicines policy and regulatory pathways.

medicinesaustralia.com.au
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Medicines Australia member companies provide financial and non-financial support to health consumer organisations. The 'Working Together' guide governs these relationships. Transparency reports on support provided are publicly available.

8Research & Development Taskforce (RDTF)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Industry taskforce focused on R&D policy issues, clinical trials, and contributing to National Health and Medical Research Strategy consultations.

medicinesaustralia.com.au
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TGA is the regulator for therapeutic goods in Australia. The Medicines Australia Code of Conduct is a TGA-imposed condition of registration. MA engages with TGA on regulatory reform and clinical trials harmonisation.

10Pharmaceutical Benefits Advisory Committee (PBAC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

PBAC is the independent committee that recommends medicines for PBS listing. MA engages with PBAC through the reimbursement process and HTA reform discussions.

medicinesaustralia.com.au
11International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Global industry association that Medicines Australia is part of, providing international perspective on pharmaceutical policy issues such as IP waivers and COVID-19 vaccine access.

medicinesaustralia.com.au
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Australia's peak body for the biotechnology sector. Overlaps with Medicines Australia around clinical trials, R&D policy and biotech ecosystem advocacy, but focuses on smaller emerging biotech rather than large research-based pharma members.

2International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
TypeOthers
Description

Geneva-based global umbrella body of which Medicines Australia is a member. Provides international policy coordination and a global Code of Practice; comparable at ecosystem level though not a direct domestic competitor.

TypeDirect peer
Description

Japanese pharma industry association with parallel advocacy, transparency and code-of-conduct functions to Medicines Australia. Similar GTM (government engagement on pricing, HTA, clinical trials).

TypeRegional player
Description

Australian peak body for medical device and diagnostics companies. Domestic counterpart operating in adjacent regulatory/reimbursement space (TGA, Prostheses List, HTA), often co-advocating alongside Medicines Australia on health policy.

TypeDirect peer
Description

European-level peak body for innovative pharma. Comparable advocacy function across multiple EU jurisdictions, including HTA coordination under the new EU HTA Regulation; analogous membership, code of practice, and policy remit.

6PhRMA — Pharmaceutical Research and Manufacturers of America
TypeDirect peer
Description

US peak body representing research-based pharmaceutical companies. Direct functional analogue to Medicines Australia: same advocacy remit (HTA/reimbursement, IP, clinical trials, Code of Conduct), same membership model, same GTM (lobbying federal government).

7Generic and Biosimilar Medicines Association of Australia (GBMA)
TypeEmerging player
Description

Australian association for generic and biosimilar manufacturers. Counter-position industry voice to Medicines Australia on PBS pricing policy but shares the same Australian policy/PBS advocacy GTM.

TypeOthers
Description

Australian alliance advocating for health and medical R&D investment. Overlaps with Medicines Australia on clinical trials, R&D Tax Incentive, and broader health-research policy advocacy in Australia.

TypeDirect peer
Description

UK trade association for research-based pharma. Closest international analogue to Medicines Australia: similar remit around NHS reimbursement, Code of Practice, clinical trials, and government engagement.

TypeDirect peer
Description

Canadian association of research-based pharmaceutical companies. Same role vis-à-vis Canadian PMPRB, CDR/pCPA reimbursement pathway, and Code of Ethical Practices — structurally a direct peer to Medicines Australia.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medicines Australia

Pharmaceutical Industry Associationmedicinesaustralia.com.au

Medicines Australia is the peak industry association representing research-based pharmaceutical companies in Australia, advocating on PBS access, HTA reform, and clinical trials policy since 1960, funded by member dues.

What Medicines Australia does

Medicines Australia is the peak industry body representing Australia's research-based pharmaceutical industry, with a history dating to 1960 when it first established its Code of Conduct. The organisation is a private, not-for-profit association headquartered in Deakin, ACT, with 11-50 employees, and is led by CEO Liz de Somer and Chair Sue MacLeman. Its members comprise companies that discover, develop, and manufacture prescription pharmaceutical products, biotherapeutic products, and vaccines in Australia — a roster that includes multinational majors such as Lilly, MSD, GSK, UCB, Amgen, Pfizer, Astellas, and Bristol Myers Squibb.

The association does not develop proprietary technology products. Its core offerings are policy advocacy, a self-regulatory Code of Conduct (currently Edition 19, with an interactive Edition 20 platform), the Strategic Agreement 2022-2027 with the Commonwealth Government, transparency reporting on industry payments to healthcare professionals, and educational programs including a Continuing Education Program. It also operates policy working groups covering the Access to Medicines Working Group, Clinical Trials / Research & Development Taskforce, Health Technology Assessment reform, the Oncology Industry Taskforce, the Pharma Australia Inclusion Group, and the Regenerative Medicines Consortium Programme.

Medicines Australia is funded entirely through recurring membership fees paid by its pharmaceutical company members; it does not sell commercial products or services. Its distribution is direct — engaging members through a Board of Directors, Advisory Council, policy working groups, briefings, and a member portal at members.medaus.com.au. The organisation's strategic significance to members derives from its role as the sole collective-bargaining counterparty to government on PBS access, HTA reform, clinical trials harmonisation, and intellectual property protection.

Medicines Australia firmographics

Firmographics
Name
Medicines Australia
Legal name
Medicines Australia
Website
https://medicinesaustralia.com.au
Company type
Private
Founded year
1960
Operating status
Operating
Headcount range
11–50 employees
Short description
Medicines Australia is the peak industry association representing research-based pharmaceutical companies in Australia, advocating on PBS access, HTA reform, and clinical trials policy since 1960, funded by member dues.
Ownership category
akta.pro rank

Medicines Australia industry classification

Industry
Product category
Pharmaceutical Industry Association
SIC
Services-Health Services (8000)
akta.pro industry
PRIMARYHLAIAKAL
Access Policy, Advocacy & Stakeholder Management
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
SECONDARYHLAJACAF
Health Technology Assessment (HTA) & Reimbursement Policy Bodies
Healthcare & Life Sciences/Public Health, Government & Regulators/Health Policy, Regulation & Compliance Authorities
SECONDARYBPADANAJ
Health, Pharmaceuticals & Medical Devices Regulatory Cooperation
Business & Public Services/International Organizations & Development/International Standards, Policy & Regulatory Cooperation

Keywords

  • Pharmaceutical industry advocacy
  • Industry association services
  • Health policy advocacy
  • Code of conduct compliance
  • Regulatory affairs representation

Where Medicines Australia is headquartered

Location

Headquarters

HQ city
Deakin
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

Medicines Australia business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Membership fees: Medicines Australia is funded through membership fees from pharmaceutical companies that discover, develop, and manufacture prescription pharmaceutical products, biotherapeutic products and vaccines in Australia.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Medicines Australia product offering

Product offering

Core offering

Medicines Australia is the peak industry association representing research-based pharmaceutical companies in Australia. Its core activities include policy advocacy with the Commonwealth Government, negotiation and administration of the Strategic Agreement 2022-2027, administration of the Code of Conduct governing industry communication about prescription medicines, member services and working groups (AMWG, RDTF, Oncology Industry Taskforce, PAIG), and engagement on HTA reform, PBS access, and clinical trials harmonisation.

Product overview

Medicines Australia is a peak industry body representing research-based pharmaceutical companies in Australia, not a product or technology company. Its offerings consist of industry advocacy, policy development, a Code of Conduct framework for member companies, publications (Annual Reports, Issues Briefs, Facts Book), educational programs (Continuing Education Program, Code workshops), transparency reporting systems, and advocacy resources. The organization does not offer commercial software products, SaaS platforms, or technology services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Strategic Agreement 2022-2027 A 5-year framework agreement between Medicines Australia and the Australian Federal Government centred on earlier patient involvement, HTA reform, investment and savings measures, and policies for faster availability of new medicines in Australia. Applicable to member pharmaceutical companies.
  • Medicines Australia Code of Conduct (Edition 19/20) Self-regulatory Code of Conduct governing the ethical promotion of prescription medicines and interactions with healthcare professionals. A TGA-imposed condition of registration for therapeutic goods that all member companies must comply with. Edition 20 is delivered via an interactive digital platform.
  • Continuing Education Program (CEP)
  • PharmAus 2025 Conference Annual flagship conference bringing together the pharmaceutical industry, government, and stakeholders for policy discussion, networking, and industry engagement.
  • Working Together Guide A guide governing the relationships between Medicines Australia member companies and health consumer organisations, including financial and non-financial support arrangements and associated transparency reporting.

Companies that use Medicines Australia

Customer profile

Named customers8 records

Segments1 record

Ideal customer profiles1 record

Medicines Australia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Medicines Australia partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and minor.

  • Commonwealth Government of AustraliacoreStrategic or Co-development Partner · 1 January 2021Medicines Australia has a 5-year Strategic Agreement (2022-2027) with the Federal Government focused on earlier patient involvement, HTA reform, and improving availability of new medicines in Australia. This includes investment and savings measures, and a reform agenda with policy improvements for faster access to medicines.
  • Access to Medicines Working Group (AMWG)coreStrategic or Co-development PartnerInternal policy working group focused on access to medicines issues, operating under the Strategic Agreement with government.
  • Clinical Trials StakeholderscoreStrategic or Co-development PartnerPartnership with Federal, State and Territory Governments and clinical trial stakeholders to implement the National One Stop Shop and National Clinical Trials Front Door for harmonising clinical trial approvals across Australia.
  • Oncology Industry TaskforcecoreStrategic or Co-development PartnerIndustry taskforce focused on oncology medicines access and policy issues, representing member companies with oncology portfolios.
  • Pharma Australia Inclusion Group (PAIG)minorStrategic or Co-development PartnerInclusion group focused on diversity and inclusion within the pharmaceutical industry in Australia.
  • Regenerative Medicines Consortium ProgrammeminorStrategic or Co-development PartnerConsortium programme focused on regenerative medicines policy and regulatory pathways.
  • Health Consumer OrganisationscoreStrategic or Co-development PartnerMedicines Australia member companies provide financial and non-financial support to health consumer organisations. The 'Working Together' guide governs these relationships. Transparency reports on support provided are publicly available.
  • Research & Development Taskforce (RDTF)coreStrategic or Co-development PartnerIndustry taskforce focused on R&D policy issues, clinical trials, and contributing to National Health and Medical Research Strategy consultations.
  • Therapeutic Goods Administration (TGA)coreStrategic or Co-development PartnerTGA is the regulator for therapeutic goods in Australia. The Medicines Australia Code of Conduct is a TGA-imposed condition of registration. MA engages with TGA on regulatory reform and clinical trials harmonisation.
  • Pharmaceutical Benefits Advisory Committee (PBAC)coreStrategic or Co-development PartnerPBAC is the independent committee that recommends medicines for PBS listing. MA engages with PBAC through the reimbursement process and HTA reform discussions.
  • International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)coreStrategic or Co-development PartnerGlobal industry association that Medicines Australia is part of, providing international perspective on pharmaceutical policy issues such as IP waivers and COVID-19 vaccine access.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Medicines Australia competitors and assessment

Company assessment

Emerging players

  • AusBiotech: Australia's peak body for the biotechnology sector. Overlaps with Medicines Australia around clinical trials, R&D policy and biotech ecosystem advocacy, but focuses on smaller emerging biotech rather than large research-based pharma members.
  • Generic and Biosimilar Medicines Association of Australia (GBMA): Australian association for generic and biosimilar manufacturers. Counter-position industry voice to Medicines Australia on PBS pricing policy but shares the same Australian policy/PBS advocacy GTM.

Others

  • International Federation of Pharmaceutical Manufacturers & Associations (IFPMA): Geneva-based global umbrella body of which Medicines Australia is a member. Provides international policy coordination and a global Code of Practice; comparable at ecosystem level though not a direct domestic competitor.
  • Research Australia: Australian alliance advocating for health and medical R&D investment. Overlaps with Medicines Australia on clinical trials, R&D Tax Incentive, and broader health-research policy advocacy in Australia.

Direct peers

  • JPMA — Japan Pharmaceutical Manufacturers Association: Japanese pharma industry association with parallel advocacy, transparency and code-of-conduct functions to Medicines Australia. Similar GTM (government engagement on pricing, HTA, clinical trials).
  • EFPIA — European Federation of Pharmaceutical Industries and Associations: European-level peak body for innovative pharma. Comparable advocacy function across multiple EU jurisdictions, including HTA coordination under the new EU HTA Regulation; analogous membership, code of practice, and policy remit.
  • PhRMA — Pharmaceutical Research and Manufacturers of America: US peak body representing research-based pharmaceutical companies. Direct functional analogue to Medicines Australia: same advocacy remit (HTA/reimbursement, IP, clinical trials, Code of Conduct), same membership model, same GTM (lobbying federal government).
  • ABPI — Association of the British Pharmaceutical Industry: UK trade association for research-based pharma. Closest international analogue to Medicines Australia: similar remit around NHS reimbursement, Code of Practice, clinical trials, and government engagement.
  • Innovative Medicines Canada: Canadian association of research-based pharmaceutical companies. Same role vis-à-vis Canadian PMPRB, CDR/pCPA reimbursement pathway, and Code of Ethical Practices — structurally a direct peer to Medicines Australia.

Regional players

  • Medical Technology Association of Australia (MTAA): Australian peak body for medical device and diagnostics companies. Domestic counterpart operating in adjacent regulatory/reimbursement space (TGA, Prostheses List, HTA), often co-advocating alongside Medicines Australia on health policy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Medicines Australia social profiles

Digital presence

Medicines Australia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medicines Australia leadership team

Management profile

Number of profiles

Profiles2 records

Medicines Australia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medicines Australia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicines Australia

What does Medicines Australia do?

Medicines Australia is the peak industry association representing research-based pharmaceutical companies in Australia. Its core activities include policy advocacy with the Commonwealth Government, negotiation and administration of the Strategic Agreement 2022-2027, administration of the Code of Conduct governing industry communication about prescription medicines, member services and working groups (AMWG, RDTF, Oncology Industry Taskforce, PAIG), and engagement on HTA reform, PBS access, and clinical trials harmonisation.

Is Medicines Australia a public or private company?

Medicines Australia is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Medicines Australia founded?

Medicines Australia was founded in 1960. It employs 11 to 50 people.

Where is Medicines Australia based?

Medicines Australia is headquartered in Deakin, Australia, in the Oceania region.

How does Medicines Australia make money?

One revenue line is on record: membership fees.

Who are Medicines Australia's main competitors?

Emerging players on record are AusBiotech and Generic and Biosimilar Medicines Association of Australia (GBMA). Others are International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) and Research Australia. Direct peers are JPMA — Japan Pharmaceutical Manufacturers Association, EFPIA — European Federation of Pharmaceutical Industries and Associations, PhRMA — Pharmaceutical Research and Manufacturers of America, ABPI — Association of the British Pharmaceutical Industry and Innovative Medicines Canada. Medical Technology Association of Australia (MTAA) is listed as a regional player.

Does Medicines Australia have an API?

No public API is recorded for Medicines Australia.

What industry is Medicines Australia in?

Medicines Australia's product category is Pharmaceutical Industry Association. Its primary akta.pro industry code is HLAIAKAL, Access Policy, Advocacy & Stakeholder Management, with a secondary code of HLAJACAF, Health Technology Assessment (HTA) & Reimbursement Policy Bodies. Its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Guardian‘Problematic precedent’: expert says Australia could be next as UK agrees to pay 25% more for new US medicinesThe UK government has agreed to pay 25% more for new US medicines, a move that Australian Health Minister Mark Butler states the government is closely monitoring for its impact on the global pharmaceutical market. While the UK National Health Service faces increased costs and potential strain on existing services, experts warn this agreement sets a problematic precedent that could pressure other nations, including Australia, to abandon value-for-money assessments for drugs.Investing.comAustralian Cell and Gene Catalyst calls for cell and gene therapies to be recognised as medical specialty By Proactive InvestorsThe Australian Cell and Gene Catalyst, a collaboration between AusBiotech and Medicines Australia, recommends that the Medical Board of Australia recognize cell and gene therapies as a medical specialty and certify specialized training programs. The call follows the Federal Government's health workforce scope of practice review, with completion targeted by end of 2024.The Pharma LetterNo need to stockpile medicines, says MA chiefElizabeth de Somer, chief executive of Medicines Australia, urged Australians to stop stockpiling medicine during the COVID pandemic, echoing Prime Minister Scott Morrison's call. She said it is imperative for the industry and nation to focus on COVID-19 and protect and treat the community.The Sydney Morning HeraldAre our doctors prescribing our drugs to help us, or to help them?A blog post questions whether doctors prescribe drugs for patients or their own benefit, citing a $8.6 million expenditure by 33 pharmaceutical companies on healthcare events. It notes a mandatory code of conduct requires reporting payments, with fines up to $300,000 for breaches.